H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
| Member | Definition | Class |
|---|
| (S)-carbinoxamine maleate | The maleic acid salt of (S)-carbinoxamine. | (S)-carbinoxamine maleate |
| acrivastine | A member of the class of pyridines that is (pyridin-2-yl)acrylic acid substituted at position 6 by a [(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl group. It is a non-sedating antihistamine used for treatment of hayfever, urticaria, and rhinitis. | acrivastine |
| alcaftadine | An imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergic conjunctivitis. | alcaftadine |
| antazoline | A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug. | antazoline |
| aripiprazole | An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. | aripiprazole |
| aripiprazole lauroxil | A dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. | aripiprazole lauroxil |
| astemizole | A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. | astemizole |
| azatadine | A benzo[5,6]cyclohepta[1,2-b]pyridine having a 1-methylpiperidin-4-ylidene group at the 11-position. | azatadine |
| azelastine | A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. | azelastine |
| azelastine hydrochloride | The hydrochloride salt of azelastine. | azelastine hydrochloride |
| benzquinamide | | benzquinamide |
| bromodiphenhydramine | A tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies. | bromazine |
| brompheniramine | Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | brompheniramine |
| carbinoxamine | An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine |
| carbinoxamine maleate | The maleic acid salt of carbinoxamine. An ethanolamine-type antihistamine, used for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine maleate |
| cetirizine | A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively. | cetirizine |
| chlorpheniramine | A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. | chlorphenamine |
| cinnarizine | | cinnarizine |
| clemastine | 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine |
| clemastine fumarate | The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine fumarate |
| clemizolpenicillin | | benzylpenicillin clemizole |
| clopenthixol | A thioxanthene derivative having a chloro substituent at the 2-position and an alkylidene group at the 10-position with undefined double bond stereochemistry. | clopenthixol |
| cyclizine | An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group. | cyclizine |
| cyclizine hydrochloride | A hydrochloride salt consisting of equimolar amounts of cyclizine and hydrogen chloride. | cyclizine hydrochloride |
| cyproheptadine | The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. | cyproheptadine |
| demethylmirtazapine | A benzazepine metabolite resulting from demethylation of the antidpressant, mirtazapine. | N-demethylmirtazapine |
| desipramine | A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group. | desipramine |
| desloratadine | Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. | desloratadine |
| dexbrompheniramine | The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | dexbrompheniramine |
| dexbrompheniramine maleate | The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | dexbrompheniramine maleate |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| diphenylpyraline | A member of the class of piperidines that is the benzhydryl ether derivative of 1-methyl-4-hydroxypiperidine. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. It is also used as the teoclate salt (piprinhydrinate) as an ingredient in compound preparations for the symptomatic relief of coughs and the common cold. | diphenylpyraline |
| diphenylpyraline hydrochloride | The hydrochloride salt of diphenylpyraline. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. | diphenylpyraline hydrochloride |
| doxylamine | | doxylamine |
| emedastine | 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis. | emedastine |
| epinastine | A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine. | epinastine |
| fexofenadine | A piperidine-based anti-histamine compound. | fexofenadine |
| hydroxyzine | A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively. | hydroxyzine |
| ketotifen | An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect. | ketotifen |
| ketotifen fumarate | An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug. | ketotifen fumarate |
| loratadine | A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders. | loratadine |
| methapyrilene | A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group. | methapyrilene |
| methapyrilene hydrochloride | A hydrochloride that is the monohydrochloride salt of methapyrilene. | methapyrilene hydrochloride |
| mianserin | A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere. | mianserin |
| mirtazapine | | mirtazapine |
| orphenadrine | A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. | orphenadrine |
| orphenadrine citrate | A citrate salt which comprises equimolar amounts of orphenadrine and citric acid. | orphenadrine citrate |
| orphenadrine hydrochloride | A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride. | orphenadrine hydrochloride |
| oxatomide | A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug. | oxatomide |
| pimozide | A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. | pimozide |
| promazine | A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position. | promazine |
| promethazine | A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. | promethazine |
| promethazine hydrochloride | The hydrochloride salt of promethazine. | promethazine hydrochloride |
| pyrilamine | An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group. | mepyramine |
| risperidone | A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2. | risperidone |
| sertindole | A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group. | sertindole |
| tau 284 | An organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic conjunctivitis. | bepotastine besylate |
| thioridazine | A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position. | thioridazine |
| trazodone | An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group. | trazodone |
| trazodone hydrochloride | A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride. | trazodone hydrochloride |
| triprolidine | An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. | triprolidine |
| triprolidine hydrochloride anhydrous | A hydrochloride resulting from the formal reaction of equimolar amounts of triprolidine and hydrogen chloride. Its monohydrate is used for the symptomatic relief of uticaria, rhinitis, and various pruritic skin disorders. | triprolidine hydrochloride (anh.) |
| zuclopenthixol | The (Z)-isomer of clopenthixol. | zuclopenthixol |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 26.1096 | 1 | 4 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 20.4839 | 1 | 2 |
| 67.9K protein | Vaccinia virus | Potency | 15.7421 | 2 | 10 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 29.9099 | 3 | 33 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 42.3369 | 2 | 5 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 29.9980 | 1 | 9 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 10.1340 | 1 | 3 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 31.6228 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 27.9369 | 9 | 126 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 21.1401 | 2 | 3 |
| arylsulfatase A | Homo sapiens (human) | Potency | 15.0581 | 1 | 13 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.7538 | 3 | 11 |
| Ataxin-2 | Homo sapiens (human) | Potency | 26.3596 | 2 | 22 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 20.6901 | 1 | 11 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 35.2096 | 2 | 16 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 7.5635 | 1 | 4 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.7596 | 1 | 8 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 38.2295 | 2 | 14 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 54.5763 | 1 | 9 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 36.5137 | 1 | 10 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 28.1374 | 1 | 6 |
| caspase-3 | Homo sapiens (human) | Potency | 36.5137 | 1 | 10 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 28.1374 | 1 | 6 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 30.3347 | 3 | 41 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 16.9550 | 2 | 11 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 24.9459 | 1 | 8 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 86.8325 | 2 | 10 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 34.2015 | 1 | 5 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 22.6973 | 1 | 3 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 24.8332 | 2 | 5 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 58.5573 | 1 | 5 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 31.8405 | 2 | 8 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 24.2351 | 1 | 8 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 24.8332 | 2 | 5 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 52.4870 | 1 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 51.7538 | 2 | 17 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 8.7224 | 1 | 19 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 15.8859 | 1 | 6 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 20.2884 | 1 | 8 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 3.8390 | 1 | 30 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 6.7176 | 1 | 33 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 7.5041 | 2 | 29 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 15.8288 | 2 | 21 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 33.2112 | 1 | 12 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 4.7098 | 3 | 23 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 15.1373 | 1 | 4 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 8.1756 | 1 | 4 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 23.7781 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 64.7274 | 1 | 6 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 15.3235 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 0.0750 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 20.6323 | 1 | 3 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 30.3132 | 11 | 133 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 30.9363 | 3 | 27 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 30.8553 | 9 | 125 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 26.6077 | 2 | 53 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 17.8347 | 4 | 29 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 28.8175 | 4 | 20 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 6.1454 | 1 | 4 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 29.2232 | 1 | 14 |
| G | Vesicular stomatitis virus | Potency | 20.2884 | 1 | 8 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| GALC protein | Homo sapiens (human) | Potency | 13.7422 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 7.5873 | 1 | 15 |
| geminin | Homo sapiens (human) | Potency | 16.6810 | 4 | 44 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.0757 | 3 | 66 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.4768 | 1 | 9 |
| GLS protein | Homo sapiens (human) | Potency | 13.7670 | 2 | 15 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 20.0850 | 1 | 2 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 30.4966 | 4 | 42 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 32.6130 | 1 | 12 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 47.1868 | 1 | 4 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 36.8727 | 2 | 15 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 15.0435 | 2 | 60 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.7672 | 1 | 5 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 62.5084 | 2 | 17 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 55.3026 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 20.2884 | 1 | 8 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 31.2354 | 2 | 10 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 28.6898 | 2 | 12 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 11.6045 | 2 | 22 |
| IDH1 | Homo sapiens (human) | Potency | 20.8357 | 1 | 6 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 20.2884 | 1 | 16 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 4.9934 | 2 | 22 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 23.1103 | 1 | 3 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 23.1103 | 1 | 3 |
| Interferon beta | Homo sapiens (human) | Potency | 21.5651 | 3 | 20 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 13.8354 | 2 | 35 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 13.6103 | 1 | 11 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.7472 | 2 | 4 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 21.0391 | 2 | 6 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 27.7630 | 1 | 9 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 19.8353 | 1 | 15 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 20.7911 | 2 | 16 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 6.9761 | 2 | 27 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 21.0391 | 1 | 3 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 21.0391 | 1 | 3 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.8481 | 3 | 13 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 13.3207 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 17.6814 | 1 | 4 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 58.0479 | 1 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 27.5667 | 4 | 35 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 22.7808 | 1 | 4 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 30.3001 | 1 | 2 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.1837 | 2 | 15 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 0.5956 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 25.0795 | 2 | 13 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 32.5187 | 3 | 40 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 0.0251 | 1 | 1 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 44.6684 | 1 | 2 |
| Parkin | Homo sapiens (human) | Potency | 31.4600 | 2 | 2 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 52.3877 | 2 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 20.4701 | 2 | 18 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 65.8443 | 1 | 10 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 25.1013 | 5 | 32 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 33.3738 | 5 | 39 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 61.8452 | 3 | 17 |
| PINK1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 7.8099 | 1 | 5 |
| polyprotein | Zika virus | Potency | 29.2232 | 1 | 14 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 14.6825 | 1 | 21 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 9.0836 | 1 | 37 |
| PPM1D protein | Homo sapiens (human) | Potency | 16.6486 | 1 | 4 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.0735 | 3 | 34 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 1 | 2 |
| progesterone receptor | Homo sapiens (human) | Potency | 30.8472 | 2 | 23 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 0.0251 | 2 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 21.5571 | 2 | 35 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 74.8287 | 1 | 5 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 23.6592 | 1 | 10 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.6881 | 3 | 59 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 18.6247 | 4 | 35 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 18.5203 | 4 | 15 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 24.4831 | 2 | 15 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 24.4831 | 2 | 15 |
| Smad3 | Homo sapiens (human) | Potency | 17.1475 | 1 | 3 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.6626 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 24.1974 | 2 | 29 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 17.4774 | 1 | 14 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 4.9992 | 1 | 4 |
| TDP1 protein | Homo sapiens (human) | Potency | 17.0138 | 2 | 82 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 38.7506 | 1 | 4 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 23.3241 | 3 | 25 |
| Thrombopoietin | Homo sapiens (human) | Potency | 10.8657 | 2 | 12 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 22.7820 | 3 | 84 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 25.3092 | 2 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.4347 | 6 | 49 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 14.8230 | 2 | 2 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 16.9765 | 1 | 5 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 23.7358 | 1 | 2 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 8.1756 | 1 | 4 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 7.8099 | 1 | 5 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 7.8099 | 1 | 5 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 38.5538 | 3 | 18 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 17.8045 | 2 | 54 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 27.8624 | 4 | 21 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 64.8138 | 1 | 8 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 32.6130 | 1 | 12 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | IC50 | 27.4278 | 5 | 5 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | Ki | 0.0187 | 1 | 3 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.3981 | 2 | 2 |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | IC50 | 0.4300 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 1.6391 | 2 | 12 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.1166 | 23 | 29 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.6244 | 9 | 19 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 1.6391 | 2 | 12 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 0.0560 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 1.1202 | 4 | 13 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | IC50 | 0.3802 | 2 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.8400 | 2 | 2 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.8400 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.3218 | 9 | 26 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | IC50 | 0.0015 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 0.3191 | 15 | 19 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0252 | 52 | 79 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.0034 | 18 | 22 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.5732 | 1 | 18 |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | IC50 | 0.0015 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.4187 | 11 | 13 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.2769 | 6 | 24 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 4 | 4 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.3723 | 7 | 25 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.4187 | 11 | 13 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0863 | 27 | 53 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.0158 | 10 | 12 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | IC50 | 0.0015 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | Ki | 0.0110 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | IC50 | 630.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 1.7006 | 2 | 2 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | Ki | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.0700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | IC50 | 1.4125 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.5012 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | Ki | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.0700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.5012 | 1 | 1 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.5012 | 1 | 1 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | IC50 | 1.4125 | 2 | 2 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.5012 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.3213 | 1 | 16 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.1638 | 2 | 17 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 1.2734 | 1 | 11 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.6054 | 15 | 30 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 25.3200 | 1 | 10 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 0.1148 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.4745 | 13 | 19 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 2.6750 | 1 | 2 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.0493 | 3 | 7 |
| 6-phosphogluconate dehydrogenase, decarboxylating | Homo sapiens (human) | Ki | 8.3000 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | IC50 | 29.1200 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 16.4610 | 1 | 1 |
| Albumin | Homo sapiens (human) | IC50 | 3.5000 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 1.8781 | 1 | 12 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 1.8624 | 1 | 12 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.4127 | 8 | 11 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 3.0142 | 9 | 10 |
| Alpha-1A adrenergic receptor | Bos taurus (cattle) | Ki | 0.0004 | 3 | 3 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0207 | 9 | 12 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.8276 | 16 | 23 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 3.7677 | 8 | 8 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.0236 | 8 | 10 |
| Alpha-1B adrenergic receptor | Mesocricetus auratus (golden hamster) | Ki | 0.0003 | 3 | 3 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.9479 | 14 | 20 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.6314 | 1 | 12 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1697 | 6 | 6 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.2004 | 6 | 19 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.1136 | 16 | 22 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.9479 | 4 | 19 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1227 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.3756 | 6 | 23 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0302 | 3 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.9201 | 3 | 17 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1227 | 2 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.5115 | 4 | 18 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0328 | 2 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.6168 | 5 | 15 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1227 | 2 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.1822 | 6 | 18 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0328 | 2 | 2 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 16.8295 | 1 | 8 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 11.0370 | 2 | 10 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | Ki | 0.2590 | 1 | 6 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 15 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 9.7650 | 7 | 12 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | IC50 | 14.4750 | 4 | 8 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 17.3820 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 10.0370 | 1 | 1 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 22.0000 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 8.0600 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 6.0450 | 1 | 1 |
| Bile acid receptor | Homo sapiens (human) | IC50 | 3.0700 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 284.2669 | 5 | 42 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 1,000.0000 | 1 | 2 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 6.6000 | 1 | 1 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Calmodulin-1 | Homo sapiens (human) | IC50 | 60.0000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 13 |
| Cathepsin D | Bos taurus (cattle) | IC50 | 0.0600 | 1 | 1 |
| Chloroquine resistance transporter | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 69.5000 | 1 | 2 |
| Cruzipain | Trypanosoma cruzi | IC50 | 212.0000 | 2 | 2 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 9.3323 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 2.3313 | 1 | 3 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 3 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 2.3355 | 2 | 9 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 0.0501 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 3 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 6.5000 | 1 | 2 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.2323 | 2 | 7 |
| D | Bos taurus (cattle) | IC50 | 0.1300 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | IC50 | 0.3277 | 6 | 11 |
| D | Rattus norvegicus (Norway rat) | Ki | 0.6573 | 6 | 12 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 1.4443 | 1 | 9 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.5806 | 10 | 20 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2815 | 3 | 8 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 1.6000 | 2 | 2 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0630 | 1 | 1 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 0.1300 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 1.3573 | 11 | 19 |
| D(2) dopamine receptor | Mus musculus (house mouse) | IC50 | 0.0230 | 1 | 2 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.3780 | 16 | 26 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.1543 | 52 | 69 |
| D(2) dopamine receptor | Mus musculus (house mouse) | Ki | 0.1120 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.2200 | 16 | 27 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 1.4233 | 3 | 14 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2815 | 3 | 8 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.2714 | 29 | 48 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.5396 | 3 | 3 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 3.5444 | 3 | 4 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2815 | 3 | 8 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.2027 | 19 | 23 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.2865 | 2 | 2 |
| Delta-type opioid receptor | Homo sapiens (human) | IC50 | 8.3695 | 2 | 2 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 4.5750 | 1 | 1 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 | 6.3400 | 1 | 1 |
| DNA gyrase subunit A | Staphylococcus aureus | IC50 | 500.0000 | 1 | 1 |
| DNA gyrase subunit B | Staphylococcus aureus | IC50 | 500.0000 | 1 | 1 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0566 | 2 | 4 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0566 | 1 | 2 |
| Endothelin-1 receptor | Homo sapiens (human) | IC50 | 0.1148 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 4.5020 | 1 | 2 |
| Estrogen receptor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| G-protein coupled receptor | Apis mellifera (honey bee) | IC50 | 73.0000 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Ki | 5.2000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | Ki | 0.8000 | 1 | 1 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Ki | 0.0040 | 1 | 1 |
| Glycogen phosphorylase, muscle form | Homo sapiens (human) | Ki | 0.0040 | 1 | 1 |
| hepatocyte nuclear factor 4-alpha isoform 2 | Homo sapiens (human) | IC50 | 39.8410 | 2 | 2 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0015 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 1.9854 | 29 | 54 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0173 | 3 | 8 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0414 | 2 | 3 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 6,960,930,555,555.5890 | 45 | 72 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | Ki | 501,187,000,000,000.0000 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 2.3400 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.9912 | 1 | 11 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.9580 | 1 | 11 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 1.4868 | 5 | 6 |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | Ki | 5.0000 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 11.2648 | 3 | 10 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | IC50 | 8.1333 | 3 | 3 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | Ki | 15.0000 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | IC50 | 3.3653 | 2 | 3 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 1.8210 | 1 | 2 |
| Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 3 | Homo sapiens (human) | IC50 | 42.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| MBT domain-containing protein 1 | Homo sapiens (human) | IC50 | 34.0000 | 1 | 1 |
| Melanocortin receptor 3 | Homo sapiens (human) | IC50 | 15.5250 | 1 | 1 |
| Melanocortin receptor 3 | Homo sapiens (human) | Ki | 13.5490 | 1 | 1 |
| Melanocortin receptor 4 | Homo sapiens (human) | IC50 | 14.0410 | 1 | 1 |
| Melanocortin receptor 4 | Homo sapiens (human) | Ki | 13.5010 | 1 | 1 |
| Melanocortin receptor 5 | Homo sapiens (human) | IC50 | 2.2630 | 1 | 1 |
| Melanocortin receptor 5 | Homo sapiens (human) | Ki | 2.1230 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 1.3787 | 2 | 3 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 0.7640 | 1 | 2 |
| Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | Homo sapiens (human) | IC50 | 3.7650 | 2 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 174.8714 | 2 | 7 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 284.1600 | 2 | 5 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 15 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 1.3683 | 2 | 14 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 0.1060 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 1.1010 | 6 | 19 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.7455 | 1 | 12 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 0.1060 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.8313 | 4 | 16 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 13.6152 | 3 | 16 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 0.1060 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.6896 | 4 | 17 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.8236 | 1 | 13 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 0.1060 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.6794 | 4 | 17 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 1 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.4733 | 1 | 14 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 1.0030 | 2 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.8218 | 4 | 18 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 16.8295 | 1 | 8 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 13.7880 | 1 | 8 |
| P2X purinoceptor 7 | Homo sapiens (human) | IC50 | 0.8300 | 1 | 1 |
| perilipin-1 | Homo sapiens (human) | IC50 | 27.7990 | 2 | 2 |
| perilipin-5 | Homo sapiens (human) | IC50 | 24.3245 | 4 | 4 |
| Platelet-activating factor receptor | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 10.1000 | 1 | 3 |
| Polycomb protein EED | Homo sapiens (human) | IC50 | 93.8000 | 1 | 1 |
| Polycomb protein EED | Homo sapiens (human) | Ki | 23.0100 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | IC50 | 1.8000 | 1 | 1 |
| Potassium channel subfamily K member 9 | Homo sapiens (human) | IC50 | 63.4000 | 1 | 1 |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 8.6739 | 53 | 141 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 6.5705 | 12 | 21 |
| Procathepsin L | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 0.0808 | 1 | 2 |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | IC50 | 65.0000 | 1 | 1 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | IC50 | 65.0000 | 1 | 1 |
| Protein orai-2 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Protein orai-3 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 | 13.0840 | 1 | 1 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Human coronavirus 229E | IC50 | 13.6450 | 1 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 11.3267 | 2 | 3 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.0719 | 1 | 3 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.8752 | 1 | 8 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.7500 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.4980 | 2 | 11 |
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 0.3400 | 1 | 1 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 24.7840 | 6 | 6 |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 | 1.1770 | 2 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 1.8118 | 3 | 6 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 2.8266 | 4 | 5 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 17.0747 | 6 | 13 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 1.1751 | 3 | 12 |
| Sodium-dependent neutral amino acid transporter B(0)AT2 | Homo sapiens (human) | IC50 | 88.0000 | 1 | 2 |
| Sodium-dependent noradrenaline transporter | Mus musculus (house mouse) | Ki | 0.2900 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.8067 | 17 | 28 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.8302 | 16 | 28 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 1.1765 | 6 | 16 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 5.0000 | 3 | 5 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.7600 | 9 | 19 |
| Sodium-dependent serotonin transporter | Mus musculus (house mouse) | Ki | 4.1000 | 1 | 1 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 0.1630 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 18.5000 | 2 | 3 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 2.8000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 33.6829 | 3 | 7 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 5.3600 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 58.2000 | 2 | 5 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 22.6667 | 2 | 3 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | Ki | 16.0000 | 1 | 1 |
| Solute carrier family 22 member 3 | Rattus norvegicus (Norway rat) | IC50 | 68.0000 | 1 | 1 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | Ki | 14.0000 | 1 | 1 |
| Solute carrier family 22 member 4 | Rattus norvegicus (Norway rat) | IC50 | 80.0000 | 1 | 1 |
| Somatostatin receptor type 2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Somatostatin receptor type 3 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Somatostatin receptor type 4 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Somatostatin receptor type 5 | Homo sapiens (human) | Ki | 4.0700 | 2 | 2 |
| Spike glycoprotein | Betacoronavirus England 1 | IC50 | 13.6450 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | IC50 | 13.6450 | 1 | 2 |
| Substance-K receptor | Homo sapiens (human) | IC50 | 2.9860 | 1 | 1 |
| Substance-K receptor | Homo sapiens (human) | Ki | 0.9950 | 1 | 1 |
| Substance-P receptor | Homo sapiens (human) | IC50 | 15.7930 | 1 | 1 |
| Substance-P receptor | Homo sapiens (human) | Ki | 8.6150 | 1 | 1 |
| Transmembrane protease serine 2 | Homo sapiens (human) | IC50 | 13.6450 | 1 | 2 |
| Transporter | Rattus norvegicus (Norway rat) | IC50 | 3.2663 | 4 | 7 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 4.4384 | 5 | 8 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 189.5000 | 1 | 2 |
| Trypanothione reductase | Trypanosoma cruzi | Ki | 137.5500 | 1 | 2 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0600 | 1 | 1 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | Ki | 0.0005 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2100 | 1 | 1 |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | Ki | 0.2590 | 1 | 2 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 3.9485 | 1 | 2 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 19.9200 | 1 | 1 |
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | IC50 | 2.0000 | 2 | 2 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | IC50 | 3.2150 | 2 | 4 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 19.2122 | 10 | 10 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 8.2253 | 8 | 8 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 8.2253 | 8 | 8 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 8.2253 | 8 | 8 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 14.5000 | 1 | 2 |
| WD repeat-containing protein 48 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| XBP1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |